• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过体内IgG抗体的裂解来阻断实验性关节炎

Blocking of experimental arthritis by cleavage of IgG antibodies in vivo.

作者信息

Nandakumar Kutty Selva, Johansson Björn P, Björck Lars, Holmdahl Rikard

机构信息

Lund University, Lund, Sweden.

出版信息

Arthritis Rheum. 2007 Oct;56(10):3253-60. doi: 10.1002/art.22930.

DOI:10.1002/art.22930
PMID:17907170
Abstract

OBJECTIVE

To investigate whether IgG-degrading enzyme of Streptococcus pyogenes (IdeS), a bacterial cysteine endopeptidase that cleaves human IgG in the hinge region, can be used for blocking the development of arthritis.

METHODS

Recombinant IdeS was purified and tested for specificity against mouse IgG. IdeS was injected intravenously into mice with collagen antibody-induced arthritis (CAIA), collagen-induced arthritis (CIA), or relapsing CIA, and its effects on arthritis development and severity were assessed.

RESULTS

IdeS efficiently cleaved mouse IgG2a/c and IgG3 in vitro. Even at low dosage (10 microg), IdeS specifically cleaved IgG2a in vivo without any apparent side effects. IdeS treatment efficiently blocked CAIA induced by IgG2a antibodies. No effect was observed when arthritis was induced with IgG2b anti-type II collagen antibodies; since IdeS does not cleave IgG2b, this indicated that IgG cleavage was the mechanism of action. IdeS treatment reduced the severity of arthritis if administered within 24 hours after the onset of clinical arthritis, but did not block ongoing severe arthritis. IdeS treatment also significantly prevented an antibody-induced relapse in mice that had chronic arthritis, and delayed the onset and reduced the severity of arthritis in classic CIA.

CONCLUSION

IdeS has therapeutic potential in IgG antibody-mediated autoimmune arthritis, representing a new and unique means of blocking pathogenic antibodies.

摘要

目的

研究化脓性链球菌的IgG降解酶(IdeS),一种能在铰链区切割人IgG的细菌半胱氨酸内肽酶,是否可用于阻止关节炎的发展。

方法

纯化重组IdeS并检测其对小鼠IgG的特异性。将IdeS静脉注射到患有胶原抗体诱导的关节炎(CAIA)、胶原诱导的关节炎(CIA)或复发性CIA的小鼠体内,并评估其对关节炎发展和严重程度的影响。

结果

IdeS在体外能有效切割小鼠IgG2a/c和IgG3。即使在低剂量(10微克)时,IdeS在体内也能特异性切割IgG2a,且无明显副作用。IdeS治疗能有效阻断由IgG2a抗体诱导的CAIA。用IgG2b抗II型胶原抗体诱导关节炎时未观察到效果;由于IdeS不切割IgG2b,这表明IgG切割是其作用机制。如果在临床关节炎发作后24小时内给药,IdeS治疗可降低关节炎的严重程度,但不能阻断正在进行的严重关节炎。IdeS治疗还能显著预防慢性关节炎小鼠的抗体诱导复发,并延缓经典CIA中关节炎的发作并降低其严重程度。

结论

IdeS在IgG抗体介导的自身免疫性关节炎中具有治疗潜力,代表了一种阻断致病抗体的新的独特方法。

相似文献

1
Blocking of experimental arthritis by cleavage of IgG antibodies in vivo.通过体内IgG抗体的裂解来阻断实验性关节炎
Arthritis Rheum. 2007 Oct;56(10):3253-60. doi: 10.1002/art.22930.
2
Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding.对链球菌内肽酶IdeS的酶学特性研究表明,它是一种半胱氨酸蛋白酶,由于存在别构位点结合,对IgG裂解具有严格的特异性。
Biochemistry. 2004 Dec 14;43(49):15540-9. doi: 10.1021/bi048284d.
3
The deficient cleavage of M protein-bound IgG by IdeS: insight into the escape of Streptococcus pyogenes from antibody-mediated immunity.IdeS 对 M 蛋白结合 IgG 的不完全切割:深入了解化脓性链球菌逃避抗体介导免疫的机制。
Mol Immunol. 2011 Oct;49(1-2):134-42. doi: 10.1016/j.molimm.2011.08.002. Epub 2011 Sep 16.
4
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis.内切糖苷酶处理消除了IgG的致关节炎性:IgG糖基化在关节炎中的重要性。
Eur J Immunol. 2007 Oct;37(10):2973-82. doi: 10.1002/eji.200737581.
5
IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection.IdeS是一种来自化脓性链球菌的高度特异性免疫球蛋白G(IgG)裂解酶,在感染过程中会被产生的特异性IgG抗体所抑制。
Infect Immun. 2006 Jan;74(1):497-503. doi: 10.1128/IAI.74.1.497-503.2006.
6
Inhibition of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 reduces the severity of collagen-induced arthritis.含Src同源2结构域蛋白酪氨酸磷酸酶底物-1的抑制作用减轻胶原诱导性关节炎的严重程度。
J Rheumatol. 2008 Dec;35(12):2316-24. doi: 10.3899/jrheum.080369. Epub 2008 Nov 1.
7
Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis.使用四种针对在胶原诱导性关节炎和类风湿性关节炎中均被识别的主要表位的单克隆抗体有效促进胶原抗体诱导的关节炎(CAIA)。
J Immunol Methods. 2005 Sep;304(1-2):126-36. doi: 10.1016/j.jim.2005.06.017.
8
Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.用 IdeS 和 EndoS(两种能降解 IgG 的链球菌酶)成功治疗实验性肾小球肾炎。
Nephrol Dial Transplant. 2010 Aug;25(8):2479-86. doi: 10.1093/ndt/gfq115. Epub 2010 Mar 10.
9
IgG immune complex-binding in macrophages from arthritis-susceptible and arthritis-resistant mice following collagen type II immunization.II型胶原免疫后,易患关节炎和抗关节炎小鼠巨噬细胞中的IgG免疫复合物结合情况。
Scand J Immunol. 2006 May;63(5):347-54. doi: 10.1111/j.1365-3083.2006.01749.x.
10
The streptococcal protease IdeS modulates bacterial IgGFc binding and generates 1/2Fc fragments with the ability to prime polymorphonuclear leucocytes.链球菌蛋白酶IdeS可调节细菌IgG Fc结合,并产生具有启动多形核白细胞能力的1/2Fc片段。
Mol Immunol. 2008 Jul;45(12):3347-53. doi: 10.1016/j.molimm.2008.04.013. Epub 2008 Jun 3.

引用本文的文献

1
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress.自身免疫性疾病中靶向新生儿Fc受体:研发进程与进展
BioDrugs. 2025 May;39(3):373-409. doi: 10.1007/s40259-025-00708-2. Epub 2025 Mar 29.
2
Imlifidase: a new interferent on serum protein electrophoresis looking as a rare plasma cell dyscrasia.伊米利酶:一种血清蛋白电泳中的新型干扰物,看似罕见的浆细胞异常增殖性疾病。
Clin Chem Lab Med. 2025 Feb 24;63(7):e175-e178. doi: 10.1515/cclm-2024-1467. Print 2025 Jun 26.
3
BD400 protects from collagen-induced arthritis through histidine metabolism.
BD400通过组氨酸代谢预防胶原诱导的关节炎。
Front Immunol. 2025 Jan 22;16:1518181. doi: 10.3389/fimmu.2025.1518181. eCollection 2025.
4
Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology.利用Fc融合技术延长IgG降解酶(IdeS)的半衰期
Eur J Immunol. 2025 Feb;55(2):e202451264. doi: 10.1002/eji.202451264. Epub 2024 Dec 20.
5
Immunomodulating Enzymes from -In Pathogenesis, as Biotechnological Tools, and as Biological Drugs.来自……的免疫调节酶在发病机制中的作用、作为生物技术工具以及作为生物药物。 (注:原文“from -In”表述似乎有误,推测可能是“from...”,这里按推测后的内容翻译,若实际不是这样,请根据正确原文调整)
Microorganisms. 2024 Jan 18;12(1):200. doi: 10.3390/microorganisms12010200.
6
Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections.链球菌感染过程中病原体驱动的内源性和治疗性抗体的降解。
Nat Commun. 2023 Oct 23;14(1):6693. doi: 10.1038/s41467-023-42572-0.
7
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.IgG 降解酶 Imlifidase 可恢复抑制剂阳性血友病 A 小鼠中 FVIII 的治疗活性。
Haematologica. 2023 May 1;108(5):1322-1334. doi: 10.3324/haematol.2022.281895.
8
Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.优化IgG降解酶治疗方案以在存在中和抗体的情况下增强腺相关病毒转导
Clin Transl Immunology. 2022 Feb 24;11(2):e1375. doi: 10.1002/cti2.1375. eCollection 2022.
9
Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.将细菌免疫逃避物纳入其中,以保护细胞疗法免受宿主抗体介导的免疫排斥。
Mol Ther. 2021 Dec 1;29(12):3398-3409. doi: 10.1016/j.ymthe.2021.06.022. Epub 2021 Jul 2.
10
Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice.使用 imlifidase 和 EndoS 进行脱敏处理可使致敏受者小鼠诱导嵌合。
Am J Transplant. 2020 Sep;20(9):2356-2365. doi: 10.1111/ajt.15851. Epub 2020 Apr 7.